# Lesson 11: Access, Regulation and Practice in Canada and the World

*Companion-podcast transcript • Sarah & Kiffer*  
*Office Hours episode to listen to after working through the lesson*

---

**Sarah:** Here's a puzzle. Under Canada's Controlled Drugs and Substances Act, ketamine sits in Schedule one, alongside MDMA. Psilocybin sits in Schedule three. As of October 2026, which of those three could a Canadian physician prescribe as a marketed medicine?

**Kiffer:** Ketamine is the only one. Ketamine injection is marketed in Canada as an anesthetic, and Health Canada's drug database gives 1972 as its original market date. The department's decision on esketamine nasal spray came in May 2020. No psilocybin or MDMA product had Canadian market authorization as of October 2026, so those two reach patients only through a clinical trial, the Special Access Program or an exemption from the Minister.

**Sarah:** So the drug in the schedule with the heavier maximum penalties is the one you can actually get on prescription.

**Kiffer:** That's the puzzle. A schedule sets how tightly the criminal law controls a substance. On indictment, the Act allows up to seven years for possessing a Schedule one substance compared with three years for Schedule three, and up to life imprisonment for trafficking compared with ten years. Whether a product can be sold as a medicine is a separate decision, made under a different law, the Food and Drugs Act, and I think a lot of confusion about access comes from running the two together.

**Sarah:** Welcome back to Office Hours. I'm Sarah.

**Kiffer:** And I'm Kiffer. That gap between control and approval runs all the way through Lesson eleven, Access, Regulation and Practice in Canada and the World, so let's start with it.

**Sarah:** Question one. If a drug is in a stricter schedule, is it harder for a patient to get?

**Kiffer:** The schedule answers a narrower question. It tells you which activities with the substance are offences unless something authorizes them. Access depends on which authorizations exist. As of October 2026, ketamine reaches patients as a marketed product, while psilocybin and MDMA reach them through a trial, the Special Access Program or an exemption. Under the Controlled Substances Regulations, in force since October first, 2026, psilocybin, LSD, DMT, mescaline and MDMA are also restricted drugs, the group of controlled substances with no approved medical use. Ketamine isn't in that group.

**Sarah:** Let me try that on a case, because I think this is where people slip.

**Kiffer:** Go ahead, and everyone listening can try it too. A hypothetical clinic in Edmonton wants to offer ketamine-assisted psychotherapy for depression. Which federal and provincial authorizations does the clinic need? Take a few seconds, and pause the audio if you'd like more time.

*(Pause)*

**Sarah:** Okay, I'll take the federal layer first. Ketamine is in Schedule one, the same schedule as MDMA, so I'd begin with a Special Access Program request for each patient, the way a clinic would for MDMA. Then I'd add the provincial layer, which is Alberta's licence for psychedelic drug treatment services.

**Kiffer:** Check that first step before you go on. What is the Special Access Program for?

**Sarah:** It's for drugs that aren't marketed in Canada, for patients with serious or life-threatening conditions when conventional treatments have failed, are unsuitable or are unavailable. And ketamine is marketed. So I did the exact thing from the opening. I read the schedule as if it told me the route. Ketamine reaches patients as a marketed product that a physician prescribes, so the Special Access Program never comes into it.

**Kiffer:** Good catch. Now try the provincial layer, which does most of the work in this case.

**Sarah:** Alberta's regulation, in force since January sixteenth, 2023, lists ketamine, including esketamine, among its designated psychedelic drugs. Its exemption from licensing covers ketamine used outside psychedelic-assisted psychotherapy, and this clinic is offering exactly that therapy, so it needs a licence. A psychiatrist prescribes, or a physician in ongoing consultation with one. The dose is given in an approved hospital, an accredited facility or the licensed provider's facility, and the patient is monitored while in an altered state. The psychotherapists must be regulated members of named colleges with the required qualifications, a psychiatrist serves as medical director, and critical incidents are notified within twenty-four hours and reported within forty-eight.

**Kiffer:** That's all correct. Now swap the drug for psilocybin in the same clinic. What changes?

**Sarah:** The provincial requirements stay the same, and the federal layer comes back. As of October 2026, psilocybin is a restricted drug with no market authorization, so each patient outside a trial needs a Special Access Program authorization naming the practitioner. The Alberta licence governs the service, and it can't authorize possession of the drug.

**Kiffer:** So one clinic and two drugs, and the authorizations depend on market status and on the therapy model. The schedule number hardly enters into it.

**Sarah:** Question two. What changed on October first, 2026, and what stayed the same?

**Kiffer:** The Controlled Substances Regulations came into force and replaced several older sets of rules, including Part J of the Food and Drug Regulations, which had governed restricted drugs. Before that date, practitioners in a Special Access Program authorization for psilocybin or MDMA relied on a class exemption under section fifty-six, which didn't allow patients to possess or transport the drug. The new regulations authorize the practitioner named in a letter of authorization to administer, sell or provide the restricted drug to a patient they're treating, and they authorize that patient to possess a drug obtained for their own use from that practitioner.

**Sarah:** So here's the question I expect a lot of people to ask. If the patient may now possess it, can she take it home?

**Kiffer:** We won't state that either way, because the sources we've checked don't confirm it. Each letter of authorization still carries its own conditions. Health Canada's 2023 notice required the drug to be used in the presence of the practitioner or a health professional they'd delegated, and that notice had not been updated for the new regulations on October seventeenth, 2026. A practitioner would need to read the letter itself and Health Canada's current guidance.

**Sarah:** And Lance shows why the question matters. The patient in that case has cluster headaches, and the 2023 request was for psilocybin at non-hallucinogenic doses that he'd take himself outside a clinic.

**Kiffer:** Which brings us to the courts, where I think the most common misreading sits. In Toth, practitioners asked in February 2022 for section fifty-six exemptions to take psilocybin mushrooms in TheraPsil's training program. The requests were refused on the ground that a clinical trial was an available option, and the Federal Court dismissed their challenge in September 2023. On June eighteenth, 2025, the Federal Court of Appeal allowed an appeal brought by seventy-three of the practitioners, along with TheraPsil and several patients. So here's a question for everyone. After that win, did the practitioners have their exemptions? Take a few seconds.

*(Pause)*

**Sarah:** No. The court sent the requests back to the Minister for a new decision. It found the refusals unreasonable because they didn't explain the departure from nineteen substantively identical exemptions granted in 2020. It also held that a professional interest in experiential training isn't a right protected by section seven of the Charter, and that the patients involved lacked standing. A MAPS bulletin of May eighth, 2026 reported that the new decision was still awaited, and no public outcome was found as of October 2026.

**Kiffer:** And Lance follows the same pattern. On May twenty-fourth, 2024, the Federal Court found the refusal unreasonable because the delegate hadn't grappled with the central arguments or considered the Charter arguments, and it ordered a new decision by a different delegate within fourteen days. In both cases, the courts reviewed the quality of the reasoning and left the substantive decision with the Minister. A headline saying that a court opened access to psilocybin has misread both cases.

**Sarah:** Then how many people has the Special Access Program actually reached? The numbers I've seen don't line up.

**Kiffer:** Here's a tempting calculation. The Federal Court recorded that, as of November 2023, one hundred fifty-three requests for psilocybin had been authorized, benefiting one hundred sixty-one patients. An opinion article published in January 2026 by clinicians associated with Roots to Thrive reported four hundred seventy-one applications between 2022 and late 2024, with about three hundred eighteen approved. Subtract one from the other and you'd say about one hundred sixty-five were approved in the year after November 2023.

**Sarah:** Those two counts measure different things. The court's figure covers psilocybin only, and it counts authorized requests, some of which covered more than one patient, since one hundred fifty-three requests benefited one hundred sixty-one people. The article counts applications for psilocybin or MDMA, and it says about three hundred eighteen. So the difference could include MDMA approvals, and we can't tell whether the article's applications are requests or patients.

**Kiffer:** And the sources differ in kind. One is a court record, and the other comes from advocates describing barriers to access, who give no source for their counts. There's a second trap, too. About three hundred eighteen of four hundred seventy-one is roughly two thirds approved, which sounds like the share of people who wanted this treatment and received it. The denominator, though, is applications that a practitioner actually filed. Anyone who never found a practitioner willing to apply is missing from it entirely. So the careful statement is that the figures come from a court record and from advocates, and that no more recent Health Canada statistic was found.

**Sarah:** Question three. When we compare access models across countries, what do the numbers let us conclude?

**Kiffer:** They let us conclude less than people hope. Let's start with a comparison matrix of two real models. The ratings are made up: Sarah and I invented them for this exercise, on a scale of one to three. For Australia's Authorised Prescriber scheme, we'll give eligibility a one, cost a one, safety oversight a three and equity a one. For Oregon's licensed services, eligibility gets a three, cost a one, safety oversight a two and equity a one. With equal weights, Australia scores six of a possible twelve, or fifty percent, and Oregon scores seven of twelve, about fifty-eight percent. Now suppose a ministry counts safety oversight three times. Which model comes out ahead? Take a few seconds.

*(Pause)*

**Sarah:** Australia gets one plus one plus three times three plus one, which is twelve. Oregon gets three plus one plus three times two plus one, which is eleven. And the maximum changes too. The weights now add to six, and six times the top rating of three is eighteen. So Australia has twelve of eighteen, about sixty-seven percent, and Oregon has eleven of eighteen, about sixty-one percent. Australia moves ahead.

**Kiffer:** And the evidence in each cell stayed exactly the same. The only thing that changed was the weight. You can even find the point where they tie. On the other three criteria, Oregon leads by two points. Each unit of weight on safety oversight adds three points for Australia and two for Oregon, which closes the gap by one, so they tie when safety counts twice. At that weight, both score nine of fifteen, or sixty percent.

**Sarah:** I'd add that ratings like these are judgements even when they're made carefully. A one for equity in both places hides two different problems. Australia's is scarcity, with sixty-three psychiatrists approved to prescribe MDMA and sixty to prescribe psilocybin between July first, 2023 and July thirty-first, 2026. Oregon's is price, since, as of October 2026, the Oregon Health Authority doesn't set or regulate prices.

**Kiffer:** Now the harder one, and it goes to safety. Researchers at Monash University reported in July 2026 that, to the end of 2025, sixty-five people had received psilocybin and one hundred twenty-three had received MDMA through Australia's scheme, with no adverse events reported. In Oregon in 2025, licensees reported seven severe adverse behavioural reactions and two severe adverse medical reactions among five thousand nine hundred thirty-five clients. It's tempting to conclude that the Australian model is the safer one, with a perfect record.

**Sarah:** Let me do Oregon first. Nine divided by five thousand nine hundred thirty-five is about 0.0015. That's about one and a half severe reactions reported per thousand clients, or 0.15 percent.

**Kiffer:** Now Australia, with zero events among one hundred eighty-eight people. Epidemiologists use a rule of thumb called the rule of three. When no events have been seen among a group of people, three divided by the number of people gives roughly the upper limit of a one-sided ninety-five percent confidence interval for the true rate. If the true rate were any higher, the chance of seeing no events at all would be under five percent.

**Sarah:** So three divided by one hundred eighty-eight, which is about 0.016, or 1.6 percent. The Australian record is consistent with a true rate as high as about 1.6 percent, which is roughly ten times Oregon's reported rate of severe reactions.

**Kiffer:** Right. A group of one hundred eighty-eight people can't tell the two apart. And the rule of three deals only with chance. It assumes that every event that happened was reported. The researchers themselves said the absence of reports could reflect appropriate screening and selection of patients, and that the reason was unclear.

**Sarah:** The two systems also count different things in different people. Australia's figure covers any adverse event reported, among patients with treatment-resistant depression or PTSD. Oregon's covers severe reactions reported by licensees, among adults who needed no diagnosis, in a year when two hundred fifty-eight people were denied services. The same Oregon summary lists nineteen milder adverse reactions as well, so its rate for any reported adverse reaction is about half a percent.

**Kiffer:** So neither figure shows which model is safer, and neither shows whether anyone benefited. These numbers describe different populations, conditions and purposes, and a fair comparison has to say so.

**Sarah:** Okay. Now the part where we disagree. Should British Columbia copy Alberta, with prescribing by a psychiatrist or a physician consulting one, and a psychiatrist as medical director of every licensed service?

**Kiffer:** I lean toward something close to it, at least to begin with. People in altered states are vulnerable, which both the Alberta government and Australia's regulator cite, and Lesson six described screening for risks such as psychosis and mania, where I think psychiatric input is worth having. Alberta's critical incident reporting matters to me as well, because the rule of three just showed how little a small count of zero can tell us. A licensed system with mandatory reporting is one way a province could learn whether its rules are working.

**Sarah:** I agree about the reporting. My worry is that a psychiatrist requirement builds scarcity in from the start. The medical routes have reached few people: one hundred sixty-one patients authorized for psilocybin through the Special Access Program by November 2023, about sixty authorized psychiatrists per drug in Australia by July 2026, and one prescriber in New Zealand in 2025. In January 2026, clinicians associated with Roots to Thrive described documentation burdens and travel to the few providers, called for a provincial billing framework, and reported that some patients turn to underground providers. Those people never show up in a licensed system's incident reports.

**Kiffer:** That's a strong point, and the harm of exclusion is real even when no form records it. Australia's experience cuts both ways, though. Its regulator started strict and, by May 2026, had relaxed the session rules so that the psychiatrist may leave the room after administration, provided a qualified therapist and a second staff member remain. Starting with tight rules and loosening them as data come in is possible. I suspect that tightening a permissive system after harms appear would be harder.

**Sarah:** That same change drew criticism from the Royal Australian and New Zealand College of Psychiatrists, while other experts had argued that requiring a psychiatrist in the room made treatment too expensive and hard to obtain. So loosening was contested too. I'd start from reach and equity, with psychiatric input at screening, delivery by trained and regulated therapists, and public funding from the first day, so that access doesn't depend on income.

**Kiffer:** Public funding is where we agree. Where we differ is the order. I'd start with oversight close to Alberta's and a scheduled review, and you'd start with fewer requirements and add them if the reports show harm.

**Sarah:** That's fair, and we agree on the practical rule. For every requirement in an access model, name the risk it's meant to address and the evidence behind it, count how many providers and patients it rules out, and set a date to review it with reported data.

**Kiffer:** That rule covers the licensed routes. The harder ground is everything that happens outside them.

**Sarah:** Question four. Most psychedelic use in Canada happens outside all of these routes. The 2025 Canadian Substance Use Survey estimated that seven percent of people aged fifteen and older, about 2.6 million people, used a psychedelic in the past year. So what can a counsellor lawfully do when a client brings that use into the room?

**Kiffer:** What follows is legal information, a general account of the law, and anyone facing a real situation needs advice from a lawyer and guidance from their college. The law here turns mostly on timing and purpose. Care after use is ordinary practice: assessing distress, helping a client make sense of an experience that has already happened, and referring. Support tied to a planned unauthorized use may carry legal risk, because it may be treated as aiding the client's possession offence. Section twenty-one of the Criminal Code makes anyone who acts for the purpose of aiding an offence a party to it, and, as of October 2026, possessing psilocybin without authority is an offence under section four of the Controlled Drugs and Substances Act.

**Sarah:** So here's a case that goes a step further. A hypothetical client tells her counsellor that she plans to take storefront psilocybin at home next month, and asks the counsellor to keep her phone on that evening so she can text if things get hard. Where does that request sit? Take a few seconds.

*(Pause)*

**Kiffer:** The legal information can't settle this one. The request is agreed in advance and tied to the planned use, and those are features it shares with the activities that may carry legal risk: preparing a client for the use, agreeing beforehand to provide integration, or being present at the session in a supporting role. Being available by text isn't one of those named activities, so it falls in the zone where the answer depends on the facts and on the purpose of the practitioner's actions. That's the kind of situation where legal advice and college guidance are most needed.

**Sarah:** That feels hard on the client, though. She's going ahead either way, and she's asking for the one thing that might help in the moment.

**Kiffer:** It is hard, and ordinary practice still leaves a counsellor a lot to offer. A counsellor can explain the boundary openly and keep working on whatever is drawing the client toward the session. A counsellor can describe the lawful routes and pass on Health Canada's public messages, on a page last modified on October eighth, 2025, that illegally produced drugs aren't tested and that the strength of magic mushrooms can vary greatly. And a counsellor can name services that exist. Nine eight eight, the Suicide Crisis Helpline, is Canada's national crisis line, by call or text at any hour, and it isn't specific to psychedelic use.

**Sarah:** And one service people may come across online, the Fireside Project's Psychedelic Support Line, served callers in the United States only as of October 2026, so it isn't an option for a client in Canada.

**Kiffer:** Let's pull it together with three things to take away.

**Sarah:** First, keep the decisions apart. A schedule sets how tightly a substance is controlled, market authorization decides whether a product can be prescribed, and a province can license the service on top of both. That's why ketamine, in Schedule one, is the marketed drug, while psilocybin, in Schedule three, needed a special route as of October 2026.

**Kiffer:** Second, read the courts and the new regulations for what they did. Toth and Lance required reasoned and consistent decisions and left access with the Minister, and the regulations in force since October first, 2026 authorize named practitioners and their patients, subject to the conditions of each letter of authorization.

**Sarah:** And third, a count is only as good as its denominator and its reporting system. Zero reported adverse events among one hundred eighty-eight people is consistent with a true rate as high as about 1.6 percent, and a count of approved applications leaves out everyone who never applied.

**Kiffer:** If you'd like more practice, rework the comparison matrix problem from this episode with your own ratings for two models, and then find the weight at which they tie.

**Sarah:** Next time, it's Lesson twelve, Ethics, Equity, Training and the Future of Psychedelic Practice, where informed consent in altered states, training, Indigenous knowledge and the commercial pressures on access come in.

**Kiffer:** Take care, everyone.

**Sarah:** See you in Lesson twelve.
